■对于一部分患有慢性膝关节疼痛的个体来说,GRFN是一种有效的治疗方法。先前的研究表明,与商业保险患者相比,医疗保险和医疗补助受益人在各种介入程序后报告的结果更差。
■评估付款人类型与GRFN治疗结果的关联。
■连续联系在三级学术中心接受GRFN的患者参与。人口统计,临床,和程序特征从电子病历中收集。结果数据在6-12个月通过标准化电话调查收集,12-24个月和≥24个月。治疗成功定义为疼痛数字评定量表(NPRS)评分从基线降低≥50%。数据采用人口统计学描述性统计分析,临床,和程序特征。进行Logistic和Poisson回归分析以检查感兴趣变量与疼痛减轻的关联。
■134例接受GRFN治疗的患者(平均年龄65.6±12.7岁,59.7%的女性),平均随访时间为23.3±11.3个月。付款人类型组成为48.5%的商业(n=65),45.5%的医疗保险(n=61),3.7%的医疗补助(n=5),1.5%的政府(n=2),和0.8%的自付(n=1)。总的来说,47.8%的患者(n=64)报告GRFN后NPRS评分降低≥50%。在调整了年龄之后,随访持续时间,Kellgren-Lawrence骨关节炎等级,基线阿片类药物使用,抗抑郁药/抗焦虑药的使用,膝关节置换史,以及放置的RFN病变的数量,logistic回归模型显示,付款人类型与治疗结局之间无统计学显著关联(OR=2.11;95%CI=0.87,5.11;p=0.098).
■在这项研究中,在调整人口统计后,临床,和程序特征,我们发现支付者类型与GRFN后的治疗成功率之间没有关联.这一观察结果与报告付款人类别与治疗成功之间关联的其他干预研究的结果形成对比。
UNASSIGNED: Genicular radiofrequency neurotomy (GRFN) is an effective treatment for a subset of individuals with chronic knee pain. Previous studies demonstrate that Medicare and Medicaid beneficiaries report worse outcomes following various interventional procedures compared with commercially insured patients.
UNASSIGNED: Evaluate the association of payer type on GRFN treatment outcomes.
UNASSIGNED: Consecutive patients who underwent GRFN at a tertiary academic center were contacted for participation. Demographic, clinical, and procedural characteristics were collected from electronic medical records. Outcome data were collected by standardized telephone survey at 6-12 months, 12-24 months and ≥24 months. Treatment success was defined as ≥50% numerical pain rating scale (NPRS) score reduction from baseline. Data were analyzed using descriptive statistics for demographic, clinical, and procedural characteristics. Logistic and Poisson regression analyses were performed to examine the association of variables of interest and pain reduction.
UNASSIGNED: One hundred thirty-four patients treated with GRFN (mean 65.6 ± 12.7 years of age, 59.7% female) with a mean follow-up time of 23.3 ± 11.3 months were included. Payer type composition was 48.5% commercial (n = 65), 45.5% Medicare (n = 61), 3.7% Medicaid (n = 5), 1.5% government (n = 2), and 0.8% self-pay (n = 1). Overall, 47.8% of patients (n = 64) reported ≥50% NPRS score reduction after GRFN. After adjusting for age, follow-up duration, Kellgren-Lawrence osteoarthritis grade, baseline opioid use, antidepressant/antianxiety medication use, history of knee replacement, and number of RFN lesions placed, the logistic regression model showed no statically significant association between payer type and treatment outcome (OR = 2.11; 95% CI = 0.87, 5.11; p = 0.098).
UNASSIGNED: In this study, after adjusting for demographic, clinical, and procedural characteristics, we found no association between payer type and treatment success following GRFN. This observation contrasts findings from other interventional studies reporting an association between payer category and treatment success.